Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.51 |
| ▸ | AR | P10275 | 6/20 | 0.49 |
| ▸ | NPC1 | O15118 | 7/20 | 0.48 |
| ▸ | RAB9A | P51151 | 7/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL240495 | 0.91 | AR (0.55) | MEN1KMT2AARNPC1RAB9A | |
| SCHEMBL29986507 | 0.90 | AR (0.54) | MEN1KMT2AARNPC1RAB9A | |
| SCHEMBL29986181 | 0.84 | AR (0.53) | MEN1KMT2AARNPC1RAB9A | |
| SCHEMBL30103590 | 0.83 | AR (0.51) | MEN1KMT2AARNPC1RAB9A | |
| SCHEMBL16696486 | 0.80 | MEN1 (0.51) | MEN1KMT2AARNPC1RAB9A | |
| SCHEMBL24662769 | 0.78 | MEN1 (0.49) | MEN1KMT2AARNPC1RAB9A | |
| SCHEMBL5783977 | 0.78 | MEN1 (0.42) | MEN1KMT2AARNPC1RAB9A | |
| SCHEMBL4128341 | 0.78 | MEN1 (0.42) | MEN1KMT2AARNPC1RAB9A | |
| SCHEMBL10304851 | 0.77 | MEN1 (0.51) | MEN1KMT2AARNPC1RAB9A | |
| 2-Phenylquinoline SCHEMBL18107977 | 0.77 | RAB9A (0.54) | MEN1KMT2AARNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8021839-B2 | Quantitative analysis; optical properties; kits | INVESTIGEN, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-7771947-B2 | Methods and compositions for rapid light-activated isolation and detection of analytes | INVESTIGEN, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-2010677-A2 | METHODS AND COMPOSITIONS FOR DETECTING POLYNUCLEOTIDES | Investigen, Inc. (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080220436-A1 | METHODS AND COMPOSITIONS FOR RAPID LIGHT-ACTIVATED ISOLATION AND DETECTION OF ANALYTES | INVESTIGEN, INC. | 2008-09-11 | — | — | US | disclosed |
| WO-2008103702-A2 | METHODS AND COMPOSITIONS FOR RAPID LIGHT-ACTIVATED ISOLATION AND DETECTION OF ANALYTES | INVESTIGEN, INC. (US) | 2008-08-28 | — | — | WO | disclosed |
| US-20070231821-A1 | Methods and compositions for detecting polynucleotides | INVESTIGEN, INC. | 2007-10-04 | — | — | US | disclosed |
| WO-2007100711-A2 | METHODS AND COMPOSITIONS FOR DETECTING POLYNUCLEOTIDES | INVESTIGEN, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070231821-A1 | Methods and compositions for detecting polynucleotides | POLN, POLRMT, POLH | MEN1 3712/4885KMT2A 4752/4885AR 3640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.